WHERE IS HYPERKALEMIA DIAGNOSED AND DOES IT MATTER? RESULTS FROM A LARGE EMR NETWORK IN THE US

Seth Kuranz¹, Timothy J Carroll¹, Jordan Donovan¹, Laura Evans¹, Jeffrey Horrigan¹ ¹TriNetX, Inc., Cambridge, MA, United States

OBJECTIVES

The aims of this analysis were to describe health outcomes and treatment-related differences among incident hyperkalemia (HK) patients diagnosed in ambulatory, inpatient, and emergency room (ER) settings.

METHODS

Patients with an incident hyperkalemia diagnosis, confirmed by serum potassium (K) \geq 5.0 mmol/L, following a kidney disease diagnosis between 2010-2018 were identified using the TriNetX platform, a U.S.-based electronic medical record network (Figure 1).

Treatment administered on the same day, health outcomes within 30-days, and retesting of K within 30-days and 1-year following the incident diagnosis of HK were compared using chi-square tests and Kaplan-Meier curves across the setting of the diagnosis: ambulatory, inpatient and ER.





TriNetX

All criteria were defined by ICD-9/10, LOINC, CPT, and RxNorm codes.



RESULTS

The mean age of patients was 68 in inpatient (N=8,875), 66 in ambulatory (N=3,471), and 67 in ER (N=1,906) care settings. ER patients were more likely to experience cardiovascular complications in the 30-days following diagnosis. Although ambulatory and ER patients had a lower probability of a second K test within the first 30 days, most patients were retested within a year of the incident HK diagnosis.

Figure 2. Outcomes 30-days after index HK event p<0.01 for all comparisons based on chi-square tests



	Inpatient		Ambulatory		ER		
	Ν	%	Ν	%	Ν	%	
Total N	8,675		3,471		1,906		
Female	4,309	50	1,706	49	923	48	p = 0.76
White	4,924	57	2,249	65	194	10	p < 0.01
Black or African American	1,990	23	587	17	1,488	78	p < 0.01
Hispanic or Latino	280	3	236	7	191	10	p < 0.01
Essential (primary) hypertension	5,735	66	2,603	75	1,503	79	p < 0.01
Hyperlipidemia, unspecified	4,943	57	1,75	50	1,010	53	p < 0.01
Type 2 diabetes mellitus	4,856	56	1,609	46	945	50	p < 0.01
Hypertensive chronic kidney disease	4,807	55	1,460	42	1,017	53	p < 0.01
Ischemic heart diseases	4,116	47	1,253	36	811	43	p < 0.01
Other hyperlipidemia	3,061	35	1,365	39	808	42	p < 0.01
Heart failure	3,950	46	997	29	702	37	p < 0.01
Atrial fibrillation and flutter	2,509	29	681	20	522	27	p < 0.01
Diseases of liver	1,597	18	581	17	400	21	p < 0.01
Cerebrovascular diseases	1,620	19	555	16	287	15	p < 0.01
Pure hypercholesterolemia	1,345	16	476	14	346	18	p < 0.01
Type 1 diabetes mellitus	787	9	367	11	233	12	p < 0.01
Mixed hyperlipidemia	356	4	252	7	199	10	p < 0.01
Antimicrobials	6,517	75	2,369	68	1,077	57	p < 0.01
Beta blockers	5,114	59	1,972	57	1,349	71	p < 0.01
Diuretics	4,668	54	1,932	56	968	51	p = 0.07
Antilipemic agents	3,744	43	1,684	49	821	43	p < 0.01
Antiarrhythmics	3,216	37	1,610	46	711	37	p < 0.01
Calcium channel blockers	3,264	38	1,330	38	619	32	p < 0.01
Ace inhibitors	2,563	30	1,317	38	647	34	p < 0.01
Antihypertensives	3,104	36	1,033	30	883	46	p < 0.01
Antianginals	1,972	23	712	21	496	26	p < 0.01
Angiotensin II inhibitors	1,123	13	593	17	260	14	p < 0.01
Alpha blockers	1,039	12	394	11	225	12	p = 0.66
Other cardiovascular agents	426	5	182	5	84	4	p = 0.42

Figure 3. Treatments administered same day as index HK event p<0.01 for all comparisons based on chi-square tests



Figure 4. Retest of K within first 30-days of index HK event

Table 1. Baseline characteristics by setting of care



Figure 5. Retest of K within first year of index HK event

CONCLUSIONS

Treatments and outcomes differed for patients who experienced a hyperkalemia event in an inpatient, ambulatory, or ER care setting. Novel treatments for hyperkalemia require a chronic diagnosis, which entails at least two K tests. Previous studies show retesting is uncommon, especially in primary care settings. However most patients in the US receive a second K test within a year of the incident hyperkalemia event, regardless of care setting.

ISPOR Europe 2019 | Copenhagen, Denmark